Low-dose aspirin use and the risk of ovarian cancer in Denmark

Annals of Oncology

Volumn 26, Issue 4, 2015, Pages 787-792

  Baandrup, Louise ^a   Kjaer, S K ^a,b   Olsen, J H ^a   Dehlendorff, C ^a   Friis, S ^a,b,c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Aspirin; Chemoprevention; Ovarian cancer

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; COLLOID CARCINOMA; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DENMARK; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EXPOSURE; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CARCINOMA; PRESCRIPTION; PRIORITY JOURNAL; REPRODUCTIVE HISTORY; RISK REDUCTION; TREATMENT DURATION; VERY ELDERLY; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CANCER STAGING; COMPARATIVE STUDY; CYSTADENOCARCINOMA, SEROUS; DOSE RESPONSE; ENDOMETRIAL NEOPLASMS; FOLLOW UP; MALE; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; REGISTER; RISK FACTOR;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; REGISTRIES; RISK FACTORS;

EID: 84926436260     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu578     Document Type: Article

References (48)

1. Cuzick J, Otto F, Baron JA et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-507.
2. Cuzick J, Thorat MA, Bosetti C et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015; 26: 47-57.
3. Rothwell PM, Price JF, Fowkes FG et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-1612.
4. Bosetti C, Rosato V, Gallus S et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-1415.
5. Baandrup L, Faber MT, Christensen J et al. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 2013; 92: 245-255.
6. Trabert B, Ness RB, Lo-Ciganic WH et al. Aspirin, nonaspirin nonsteroidal antiinflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 2014; 106.
7. Brasky TM, Liu J, White E et al. Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health Initiative. Int J Cancer 2014; 135: 1869-1883.
8. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
9. Blenstrup LT, Knudsen LB. Danish registers on aspects of reproduction. Scand J Public Health 2011; 39(7 Suppl): 79-82.
10. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39(7 Suppl): 38-41.
11. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39(7 Suppl): 42-45.
12. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39(7 Suppl): 30-33.
13. Jensen VM, Rasmussen AW. Danish Education Registers. Scand J Public Health 2011; 39(7 Suppl): 91-94.
14. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39(7 Suppl): 22-25.
15. Rothman K, Greenland S, Lash TL. Modern Epidemiology. 3rd edition. Philadelphia, PA: Wolters Kluwer Health, Lippincott Williams & Wilkins, 2008; Chapter 8.
16. Hankinson SE, Danforth KN. Ovarian cancer. In Schottenfeld D, Fraumeni JF, Jr (eds), Cancer Epidemiology and Prevention, 3rd edition. New York: Oxford University Press, 2006; Chapter 52.
17. Baandrup L, Friis S, Dehlendorff C et al. Prescription use of paracetamol and risk for ovarian cancer in Denmark. J Natl Cancer Inst 2014; 106.
18. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2013.
19. Lo-Ciganic WH, Zgibor JC, Bunker CH et al. Aspirin, nonaspirin nonsteroidal antiinflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology 2012; 23: 311-319.
20. Prizment AE, Folsom AR, Anderson KE. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2010; 19: 435-442.
21. Schildkraut JM, Moorman PG, Halabi S et al. Analgesic drug use and risk of ovarian cancer. Epidemiology 2006; 17: 104-107.
22. Cramer DW, Harlow BL, Titus-Ernstoff L et al. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998; 351: 104-107.
23. Rosenberg L, Palmer JR, Rao RS et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 933-937.
24. Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002; 22: 303-309.
25. Lacey JV, Jr, Sherman ME, Hartge P et al. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 2004; 108: 281-286.
26. Lurie G, Terry KL, Wilkens LR et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 2010; 21: 1731-1741.
27. Ammundsen HB, Faber MT, Jensen A et al. Use of analgesic drugs and risk of ovarian cancer: results from a Danish case-control study. Acta Obstet Gynecol Scand 2012; 91: 1094-1102.
28. Tavani A, Gallus S, La VC et al. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 2000; 11: 1171-1173.
29. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A et al. Aspirin and epithelial ovarian cancer. Prev Med 2001; 33: 682-687.
30. Wernli KJ, Newcomb PA, Hampton JM et al. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 2008; 98: 1781-1783.
31. Setiawan VW, Matsuno RK, Lurie G et al. Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 2012; 21: 1441-1449.
32. Moysich KB, Mettlin C, Piver MS et al. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 903-906.
33. Fairfield KM, Hunter DJ, Fuchs CS et al. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002; 13: 535-542.
34. Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008; 122: 170-176.
35. Pinheiro SP, Tworoger SS, Cramer DW et al. Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol 2009; 169: 1378-1387.
36. Murphy MA, Trabert B, Yang HP et al. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control 2012; 23: 1839-1852.
37. Friis S, Sorensen HT, McLaughlin JK et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003; 88: 684-688.
38. Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL. Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol 2008; 167: 1430-1437.
39. Wu AH, Pearce CL, Tseng CC et al. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 2009; 124: 1409-1415.
40. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527.
41. Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47-55.
42. Cook NR, Lee IM, Zhang SM et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159: 77-85.
43. Thorat MA, Cuzick J. Role of aspirin in cancer prevention. Curr Oncol Rep 2013; 15: 533-540.
44. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012; 9: 259-267.
45. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-140.
46. Langley RE, Burdett S, Tierney JF et al. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 2011; 105: 1107-1113.
47. Schmidt M, Hallas J, Friis S. Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999-2012. Clin Epidemiol 2014; 6: 155-168.
48. Winther K, Husted SE, Vissinger H. Low dose acetylsalicylic acid in the antithrombotic treatment of patients with stable angina pectoris and acute coronary syndromes (unstable angina pectoris and acute myocardial infarction). Pharmacol Toxicol 1994; 74: 141-147.